AUG 20, 2026 · PHASE 2 TRIAL
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
ClinicalTrials.gov
Phase 2 trial in a recruiting stage with no results reported; measures a surrogate endpoint (ctDNA clearance) in an adjuvant minimal residual disease setting.
Reported
Planned sample size42
Primary outcome measureRate of circulating tumor deoxyribonucleic…
PhasePHASE 2